Oncolytics Biotech(R) Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path.

Oncolytics Biotech Inc., a clinical-stage company specializing in immunotherapy for oncology, has announced key progress and upcoming studies for breast and pancreatic cancer treatments. The company's recent BRACELET-1 study showed that pelareorep combination therapy could improve outcomes in HR+/HER2- breast cancer patients. They plan to submit a pelareorep + paclitaxel combination therapy breast cancer trial to the FDA in early 2025. Additionally, Oncolytics Biotech is continuing to develop pelareorep in gastrointestinal cancers and is evaluating its efficacy in anal cancer and pancreatic cancer. [Extracted from the article]